可溶性グアニル酸シクラーゼ：パイプライン製品の分析

当レポートでは、可溶性グアニル酸シクラーゼを標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

• 調査範囲

可溶性グアニル酸シクラーゼ 概要

治療薬の開発

• 開発中の製品：開発段階別
• 開発中の製品：治療領域別
• 開発中の製品：症状別

パイプライン製品の概況

• 後期段階の製品
• 初期段階の製品

企業で開発中の製品

大学／機関で開発中の製品

治療薬の評価

• 単剤/併用治療薬の場合
• 作用機序別
• 投与経路別
• 分子タイプ別

治療薬開発に従事している企業

• Bayer AG
• Boehringer Ingelheim GmbH
• Ironwood Pharmaceuticals, Inc.
• Mallinckrodt Plc
• NicOx S.A.
• SynZyme Technologies, LLC

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

主なニュースおよびプレスリリース

付録

図表

List of Tables

List of Tables

• Number of Products under Development by Stage of Development, H2 2020
• Number of Products under Development by Therapy Areas, H2 2020
• Number of Products under Development by Indications, H2 2020
• Number of Products under Development by Companies, H2 2020
• Products under Development by Companies, H2 2020
• Number of Products under Investigation by Universities/Institutes, H2 2020
• Products under Investigation by Universities/Institutes, H2 2020
• Number of Products by Stage and Mechanism of Actions, H2 2020
• Number of Products by Stage and Route of Administration, H2 2020
• Number of Products by Stage and Molecule Type, H2 2020
• Pipeline by AntiRadical Therapeutics LLC, H2 2020
• Pipeline by Bayer AG, H2 2020
• Pipeline by Boehringer Ingelheim International GmbH, H2 2020
• Pipeline by Cyclerion Therapeutics Inc, H2 2020
• Pipeline by Gurus BioPharm, H2 2020
• Pipeline by NicOx SA, H2 2020
• Pipeline by Nitric Oxide Innovations LLC, H2 2020
• Pipeline by Novartis AG, H2 2020
• Pipeline by Novoteris LLC, H2 2020
• Pipeline by Toa Eiyo Ltd, H2 2020
• Pipeline by Topadur Pharma AG, H2 2020
• Dormant Products, H2 2020
• Discontinued Products, H2 2020

List of Figures

List of Figures

• Number of Products under Development by Stage of Development, H2 2020
• Number of Products under Development by Therapy Areas, H2 2020
• Number of Products under Development by Top 10 Indications, H2 2020
• Number of Products by Mechanism of Actions, H2 2020
• Number of Products by Stage and Mechanism of Actions, H2 2020
• Number of Products by Routes of Administration, H2 2020
• Number of Products by Stage and Routes of Administration, H2 2020
• Number of Products by Molecule Types, H2 2020
• Number of Products by Stage and Molecule Types, H2 2020

Summary:

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The latest report Soluble Guanylate Cyclase - Pipeline Review, H2 2020, outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 4, 4 and 14 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Respiratory, Infectious Disease, Oncology, Gastrointestinal, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Glaucoma, Coronavirus Disease 2019 (COVID-19), Pulmonary Arterial Hypertension, Diabetic Nephropathy, Lung Disease, Ocular Hypertension, Vaso-Occlusive Crisis Associated With Sickle Cell Disease, Acute Heart Failure, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Asthma, Chronic Kidney Disease (Chronic Renal Failure), Chronic Obstructive Pulmonary Disease (COPD), Chronic Thromboembolic Pulmonary Hypertension, Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Cystic Fibrosis, Diabetic Foot Ulcers, Diabetic Retinopathy, Diastolic Heart Failure, Dry (Atrophic) Macular Degeneration, Ischemic Stroke, Liver Diseases, Liver Fibrosis, MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes), Mycobacterium Infections, Non-Alcoholic Steatohepatitis (NASH), Open-Angle Glaucoma, Osteoporosis, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Pneumonia, Pressure Ulcers, Prostate Cancer, Pulmonary Hypertension, Raynauds Disease, Skin Ulcers, Stroke, Systolic Heart Failure and Vascular Dementias.

Furthermore, this report also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

• The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
• The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics

Reasons to Buy:

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

• Introduction
• Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview
• Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development
• Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment
• Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development
• Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles
• Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Products
• Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products
• Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Product Development Milestones
• Appendix